Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106 CD20-Targeted CAR T in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia
11 juin 2021 06h30 HE
|
Mustang Bio, Inc.
Data presented at the European Hematology Association 2021 Virtual Congress show favorable safety profile and compelling clinical activity 93% overall response rate and 67% complete response rate in...